Popular Trials
Cholinergic Agonist
Pilocarpine +1 More for Presbyopia
The current study aims to assess the use of pilocarpine and brimonidine to improve near visual acuity in patietns with monofocal intraocular lenses. Thirty-three subjects with be enrolled and baseline visual acuity with be measured at near and distance. This will be compared to visual acuity after drop administration over 6 hours. A quality of life questionnaire will also be evaluated.
Bandage Contact Lens
Bandage Contact Lenses for Corneal Abrasions
Two percent of all patients presenting to the Emergency Departments have complaints involving the eye. Corneal abrasions are a common diagnosis with patients with eye pain and often cause significant discomfort. Current treatment includes a thorough evaluation of the eye followed by patching, empiric antibiotics, cycloplegics and oral pain medicines. This study will be a randomized controlled trial to determine the safety and efficacy of BCLs. It will involve the initial patient evaluation followed by a return visit to the Emergency Department within 36 hours for re-examination. At each visit, the patient will be assessed for the size and location of the abrasion along with their report of pain using a visual analog scale. Data will be recorded on a standard data collection sheet. Telephone contact will be made at 30 days to ensure resolution of abrasion and that no complications ensued.
Implant
MINIject™ Implant for Glaucoma
This trial is testing a small device called the MINIject™ implant, which is designed to help lower eye pressure in people with primary open-angle glaucoma. The device works by making it easier for fluid to drain from the eye, reducing pressure and potentially preventing vision loss.
Rho-kinase Inhibitor
Netarsudil Ophthalmic +1 More for Normal Tension Glaucoma
Glaucoma is the second leading cause of blindness and the first leading cause of irreversible vision loss worldwide. The intraocular pressure (IOP) is the only modifiable risk factor for all the spectrum of glaucoma. Reducing IOP in glaucoma increases the likelihood of preventing progression of the disease and preserving the quality of life of the patient. Although prostaglandin analogs (PGAs) and prostamides (PMs) are de facto first-line treatment options for managing glaucoma, it is a common clinical experience to see their treatment effects plateau to a level beyond which no clinically significant IOP reduction is likely. It is also common to find minimal IOP treatment effects in the following conditions: patients with normal tension glaucoma (NTG), patients with thicker central corneal thickness (CCT), and patients with higher levels of corneal hysteresis (CH). CH is a possible proxy for the ability of the scleral tissue around the optic nerve to dissipate energy away from the optic nerve fibers. Netarsudil, a rho-kinase inhibitor was recently approved by the FDA for the treatment of glaucoma and ocular hypertension. There is a paucity of research on the efficacy of netarsudil in patients with NTG, thicker CCT, and higher levels of CH. This study aims to investigate the above issues by evaluating the efficacy of netarsudil and bimatoprost in subjects with NTG, thicker corneas, and higher levels of CH. Hypotheses * Netarsudil will have non-inferior efficacy compared to Bimatoprost in treating NTG. * Corneal thickness and corneal hysteresis will reduce the efficacy of netarsudil similar to bimatoprost in NTG. * Netarsudil will change corneal thickness and corneal hysteresis similar to bimatoprost in NTG.
Popular Filters
Trials for Glaucoma Patients
Lumify for Glaucoma Side Effects
This trial is testing Lumify™ eye drops, which help reduce eye redness, in glaucoma patients who are already using Brimonidine eye drops. These patients often have red eyes as a side effect of their current treatment. Lumify™ works by making the blood vessels in the eyes smaller, which helps to reduce redness.
Behavioural Intervention
Osteopathic Manipulative Treatment for Glaucoma
This trial is testing whether a hands-on therapy called Osteopathic Manipulative Treatment (OMT) can help lower eye pressure in patients with high eye pressure or glaucoma. The therapy involves manual adjustments that may improve fluid drainage in the eye. The study aims to see if this therapy can significantly reduce eye pressure.
Behavioural Intervention
Pulsed Electromagnetic Field Therapy for Glaucoma
Glaucoma is among the leading causes for blindness in the western world. Elevated intraocular pressure (IOP) has been identified as the most important risk factor. However, some patients progress despite adequate IOP lowering while some subjects with elevated IOP never develop glaucoma. Other patients develop glaucoma although IOP measurements were always in the normal range. Therefore, other factors must be involved. In the last years, studies using MRI have been performed and evidence has accumulated that also changes in retrobulbar structures are present, in particular in the lateral geniculate nucleus and the visual cortex. However, these studies were limited by the low spatial resolution of the MRI instruments used.
Procedure
Nanodropper Device for Glaucoma
This trial is testing if a device called the Nanodropper, which gives smaller eye drops, works as well as regular eye drops for adults with stable glaucoma or high eye pressure. The goal is to see if using less liquid can still effectively lower eye pressure.
Trials for Cataract Patients
Intraocular Lens
Hoya AF-1 IOL for Cataract
The doctors participating in this study are looking to show improved vision with the HOYA AF-1 aspheric intraocular lens after cataract surgery. They will also study the use of Revital Vision (neuro-sensory testing) in providing the highest potential for improved vision.
Intraocular Lens
TECNIS® Intraocular Lens for Cataracts
This trial will be conducted at multiple locations on both sides of the body and will involve an intervention. It will be carefully controlled and will involve random assignment of participants. The trial will be masked, meaning
Trials With No Placebo
Intraocular Lens
Hoya AF-1 IOL for Cataract
The doctors participating in this study are looking to show improved vision with the HOYA AF-1 aspheric intraocular lens after cataract surgery. They will also study the use of Revital Vision (neuro-sensory testing) in providing the highest potential for improved vision.
View More Related Trials
Frequently Asked Questions
Introduction to intraocular lens
What are the top hospitals conducting intraocular lens research?
When it comes to advancing the field of intraocular lens treatments, several hospitals are leading the way with their cutting-edge clinical trials. In Sioux Falls, Vance Thompson Vision is at the forefront, conducting three active trials focused on this innovative lens technology. With a clean slate of zero previous trials, they are dedicated to exploring new possibilities for improved vision and eye health. Meanwhile, in Columbus, The Ohio State University College of Optometry is making strides with two ongoing intraocular lens trials. Like Vance Thompson Vision, they have yet to conduct any previous studies in this specific area but are committed to pushing boundaries and expanding knowledge. ProCare Vision Center in Granville also joins this group with two active trials aimed at enhancing intraocular lenses' effectiveness and patient outcomes.
Further contributing to these advancements is Eye Surgical and Medical Associates located in Visalia; similarly engaged in two current clinical investigations which seek ways into optimizing functionality for such specialized lenses while lacking historical tracks as none had been performed before.This pattern continues as Sacco Eye Group situated in Vestal commits its resources towards addressing limitations related specifically to intraocular lens utilization through their pair of ongoing experimental projects; an impressive feat considering no prior explorations were recorded either.
These hospitals serve as beacons of hope for individuals suffering from various ocular conditions that can be addressed with intraocular lens treatments. By pushing boundaries through research and innovation, these institutions strive to improve sight restoration techniques and provide patients with enhanced quality of life. As the world progresses towards better understanding ocular health issues like cataracts or refractive errors requiring corrective measures such as implantation procedures involving artificial lenses – or simply known as IOLs - we can anticipate exciting breakthroughs emanating from efforts made by visionary establishments like those mentioned above
Which are the best cities for intraocular lens clinical trials?
For those seeking clinical trials related to intraocular lenses, several cities have emerged as leading hubs of research and innovation. In San Antonio, Texas, there are 7 active trials underway investigating the efficacy of enVista MX60EF, investigational Lens Device, TC-002, and other interventions. Columbus, Ohio follows closely with 6 ongoing studies focused on lens wear experience, enVista MX60EF treatment options among others. Toronto in Ontario boasts 5 active trials examining test contact lenses, control contact lenses such as Alcon 1 piece SA60AT lens and more. Similarly in Waterloo Ontario there are also 5 active trials studying non-contact lens wearers and various types of test and control contact lenses. Lastly Granville Ohio features 4 active trials exploring factors like lens wear experience using LID226397 or AOfAHP alongside different test and control contact lenses. These cities offer individuals interested in intraocular lens clinical trials access to cutting-edge research opportunities that contribute to advancing eye care treatments for better patient outcomes.
Which are the top treatments for intraocular lens being explored in clinical trials?
In the realm of intraocular lens (IOL) research, several promising treatments are currently under exploration in clinical trials. Leading the pack is IOL treatment A, with five active trials dedicated to studying its efficacy and potential benefits. Additionally, IOL treatment B has emerged as another contender with three ongoing trials showcasing its capabilities. Finally, not to be overlooked is IOL treatment C that has garnered attention through two current studies focused on assessing its effectiveness in improving vision outcomes for patients. As these clinical trials progress and results accumulate, they hold the promise of enhancing our understanding and expanding options for individuals seeking improved visual health through innovative IOL treatments.
What are the most recent clinical trials for intraocular lens?
Exciting advancements in the field of intraocular lens (IOL) technology have emerged from recent clinical trials, offering promising prospects for improved vision and patient outcomes. One notable study investigated the efficacy of Methazolamide 25 mg as an adjunct treatment for IOL placement, aiming to enhance post-operative results. Additionally, a Phase 3 trial delved into the potential benefits of Yutiq 0.18 MG Drug Implant when used in conjunction with IOLs, providing hope for enhanced vision correction solutions. Another Phase 3 trial evaluated TC-002's effectiveness as an alternative option for IOL patients. With these groundbreaking studies shedding light on innovative interventions, individuals seeking optimal visual acuity through IOL technology can anticipate new possibilities on the horizon.
What intraocular lens clinical trials were recently completed?
Recently, several clinical trials have been concluded to evaluate the effectiveness of intraocular lenses (IOLs), a crucial component in cataract surgery. These studies aim to enhance vision outcomes and address specific patient needs. Notably, the trial for IOL-100 by LensGen was completed in October 2021, showcasing its potential as an innovative adjustable lens technology. Similarly, another study sponsored by Johnson & Johnson Vision on their TECNIS Synergy™ IOL reached completion in September 2021. Lastly, Alcon's PanOptix® trifocal IOL underwent a successful trial that ended in January 2021. The conclusion of these trials represents important advancements towards improving visual outcomes and providing better options for patients undergoing cataract surgery with IOL implantation.